<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Polysaccharide-iron complex: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Polysaccharide-iron complex: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Polysaccharide-iron complex: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11833" href="/d/html/11833.html" rel="external">see "Polysaccharide-iron complex: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="89426" href="/d/html/89426.html" rel="external">see "Polysaccharide-iron complex: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F211213"><span class="drugH1">Brand Names: US</span>
<ul>
<li>EZFE 200 [OTC];</li>
<li>Ferrex 150 [OTC];</li>
<li>Ferric x-150 [OTC];</li>
<li>IFerex 150 [OTC];</li>
<li>NovaFerrum 50 [OTC];</li>
<li>NovaFerrum Pediatric Drops [OTC];</li>
<li>NovaFerrum [OTC];</li>
<li>Nu-Iron [OTC];</li>
<li>Poly-Iron 150 [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F211222"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Iron Preparations</li></ul></div>
<div class="block doa drugH1Div" id="F211214"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b>
<b>Dosage expression: </b>Dose is expressed in terms of elemental iron; the strength of each capsule or concentration of liquid represents the amount of elemental iron (eg, a 150 mg capsule contains 150 mg of elemental iron). <b>Formulation:</b> Enteric-coated and slow/sustained-release preparations are generally not preferred due to poor absorption (Hershko 2014; Liu 2012). <b>Route of administration:</b> IV iron replacement is preferred over oral replacement in several clinical situations (eg, poor GI absorption, lack of response to or poor tolerability of oral iron, chronic kidney disease, active inflammatory bowel disease, cancer, chronic or extensive blood loss) (Auerbach 2021).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a53f6d47-419d-442f-b670-a934e4739018">Iron deficiency or iron-deficiency anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron deficiency or iron-deficiency anemia: Oral:</b> 50 to 200 mg of elemental iron (1 tablet or equivalent as liquid) once every other day or on Monday, Wednesday, and Friday (Liu 2012; Stoffel 2017; Stoffel 2020; Stoltzfus 1998; WHO 2001). <b>Note:</b> Daily dosing has been shown to result in decreased absorption but may be reasonable in some individuals to improve adherence (Auerbach 2021; Stoffel 2017; Stoffel 2020).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F51154004"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F51154005"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F211215"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F211218"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="89426" href="/d/html/89426.html" rel="external">see "Polysaccharide-iron complex: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Multiple concentrations of polysaccharide iron complex oral liquid exist; close attention must be paid to the concentration when ordering and administering polysaccharide iron complex; incorrect selection or substitution of one polysaccharide iron complex liquid for another without proper dosage volume adjustment may result in serious over- or underdosing.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Dosages are expressed in terms of <b>elemental</b> iron.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="de032cb1-ec1e-4269-8e0c-b7218680e8a4">Dietary supplementation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary supplementation:</b>
<b>Note</b>: Refer to product-specific labeling for approved pediatric ages.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;12 years: Oral liquid: Oral: 15 mg <b>elemental</b> iron daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: 50 mg <b>elemental</b> iron daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21c9d7bf-0c30-42f8-82af-9a4a30126334">Iron-deficiency anemia, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AAP recommendations: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Infants ≥4 months (exclusively fed human milk or human milk provides &gt;50% of nutrition without iron fortified food): Oral: 1 mg<b> elemental</b> iron/kg/day; supplementation should be continued until sufficient iron is provided in complementary foods (AAP [Baker 2010]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>WHO recommendations:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Areas where anemia prevalence is ≥40%:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children &lt;2 years: Oral: 10 to 12.5 mg <b>elemental </b>iron daily for 3 consecutive months in a year (WHO 2016b).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to &lt;5 years: Oral: 30 mg <b>elemental </b>iron daily for 3 consecutive months in a year (WHO 2016b).</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥5 to 12 years: Oral: 30 to 60 mg <b>elemental </b>iron daily for 3 consecutive months in a year (WHO 2016b).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescent menstruating patients (nonpregnant patients of reproductive potential): Oral: 30 to 60 mg <b>elemental </b>iron daily for 3 consecutive months in a year (WHO 2016a).</p>
<p style="text-indent:-2em;margin-left:6em;">Areas where anemia prevalence 20% to &lt;40%: Weekly intermittent dosing:</p>
<p style="text-indent:-2em;margin-left:8em;">Children 2 to &lt;5 years: Oral: 25 mg <b>elemental</b> iron once <b>weekly</b> for 3 consecutive months, then alternating 3 months off supplementation, 3 months on supplementation (WHO 2011).</p>
<p style="text-indent:-2em;margin-left:8em;">Children 5 to 12 years: Oral: 45 mg <b>elemental</b> iron once <b>weekly</b> for 3 consecutive months, then alternating 3 months off supplementation, 3 months on supplementation (WHO 2011).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="035e1654-7eac-49da-83bd-23b3e0ca305a">Iron-deficiency anemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron-deficiency anemia, treatment: </b>Infants, Children, and Adolescents: Oral: Initial: 3 mg <b>elemental</b> iron/kg/day as a single daily dose (Kazal 2002; Oski 1993; Powers 2017; Reeves 1985) up to 60 to 120 mg <b>elemental</b> iron once daily (AAP [Kleinman 2019]); higher doses may be needed in select patients; dosage range: 3 to 6 mg<b> elemental</b> iron/kg/day in 1 to 3 divided doses; usual maximum daily dose: 150 to 200 mg<b> elemental</b> iron/<b>day</b> (ASPEN [Corkins 2015]; Kliegman 2020; Zlotkin 2001); once-daily administration may be preferred for ease of administration and adherence (Zlotkin 2001). Studies in iron-depleted adults suggest that iron absorption may be improved by less frequent dosing (alternate-day dosing, or once daily versus multiple daily doses) (Moretti 2015; Stoffel 2017).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51153909"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51153910"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosing adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F211203"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Constipation, darkening of stools, epigastric pain, gastrointestinal irritation, nausea, stomach cramps, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dental discoloration, diarrhea, heartburn</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urine discoloration</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Local irritation</p></div>
<div class="block coi drugH1Div" id="F23887951"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Known hypersensitivity to polysaccharide-iron complex or any component of the formulations; hemochromatosis; hemosiderosis</p></div>
<div class="block war drugH1Div" id="F11392044"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Stool discoloration: Oral iron preparations commonly cause dark or black stools; patients should be informed of the effect.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: <b>Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Oral iron formulations: Immediate-release oral iron products are preferred for treatment of iron deficiency anemia; enteric-coated and slow-/sustained-release preparations are not desired due to poor absorption (Hershko 2014; Liu 2012).</p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions and intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Excipient: Some formulations may contain tartrazine, which is associated with allergic-type reactions. Although rare, hypersensitivity is more frequently seen in individuals with aspirin allergy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Investigate type of anemia and potential underlying causes (eg, recurrent blood loss) prior to initiating iron supplementation.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878596"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Consider all iron sources when evaluating the dose of iron, including combination products, infant formulas, and liquid nutritional supplements.</p></div>
<div class="block foc drugH1Div" id="F211207"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">EZFE 200: 200 mg [non-toxic; contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferrex 150: 150 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #5 (tartrazine)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ferric x-150: 150 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), fd&amp;c yellow #5 (tartrazine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">IFerex 150: 150 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovaFerrum 50: 50 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nu-Iron: 150 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Poly-Iron 150: 150 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #5 (tartrazine)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Liquid, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovaFerrum: Polysaccharide-iron complex 125 mg and cholecalciferol 100 units per 5 mL (180 mL) [contains sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">NovaFerrum Pediatric Drops: 15 mg/mL (120 mL) [alcohol free, dye free, gluten free, lactose free, sodium free, sugar free; contains sodium benzoate; raspberry-grape flavor]</p></div>
<div class="block geq drugH1Div" id="F211198"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F211211"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (EZFE 200 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">434.8 (200 Fe) mg (per each): $0.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Ferrex 150 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.15</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (IFerex 150 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (NovaFerrum 50 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Nu-Iron Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Poly-Iron 150 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Polysaccharide Iron Complex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (Hematex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $0.08</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (NovaFerrum Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/5 mL (per mL): $0.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Liquid</b> (NovaFerrum Pediatric Drops Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg/mL (per mL): $0.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Hematex Iron Complex Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $0.30</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F53076023"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Oral: Shake liquid well prior to administration.</p></div>
<div class="block admp drugH1Div" id="F52613617"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with water or juice prior to breakfast and/or between meals for maximum absorption (Kliegman 2020; Oski 1993); may administer with food if GI upset occurs; do not administer with milk or milk products (Powers 2017). Shake liquid well prior to administration.</p></div>
<div class="block use drugH1Div" id="F211208"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Iron deficiency or iron-deficiency anemia:</b> Management (prevention and treatment) of iron-deficiency anemia.</p></div>
<div class="block cyt drugH1Div" id="F13299906"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F6222429"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Iron Preparations may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Iron Preparations.  Management: Separate administration of alpha-lipoic acid from that of any iron-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral iron-containing products at lunch or dinner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Iron Preparations. Management: No action is likely necessary for the majority of patients who only use antacids intermittently or occasionally. Consider separating doses of oral iron and antacids in patients who require chronic use of both agents and monitor for reduced iron efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Iron Preparations may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with iron preparations under fed conditions, but coadministration with or 2 hours after an iron preparation is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefdinir: Iron Preparations may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible. Separate doses by at least 2 hours if combined. Iron-containing infant formulas do not appear alter cefdinir pharmacokinetics, but red-appearing, non-bloody stools may develop when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimercaprol: May enhance the nephrotoxic effect of Iron Preparations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Iron Preparations may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral iron. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral iron. Alternatively, dolutegravir and oral iron can be taken together with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entacapone: Iron Preparations may decrease the serum concentration of Entacapone.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ferric Hydroxide Polymaltose Complex: May decrease the serum concentration of Iron Preparations. Specifically, the absorption of oral iron salts may be reduced. Management: Do not administer intravenous (IV) ferric hydroxide polymaltose complex with other oral iron preparations. Therapy with oral iron preparations should begin 1 week after the last dose of IV ferric hydroxide polymaltose complex.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa: Iron Preparations may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Iron Preparations may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: Iron Preparations may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron preparations and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron preparations or levothyroxine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methyldopa: Iron Preparations may decrease the serum concentration of Methyldopa.  Management: Consider separating doses of methyldopa and orally administered iron preparation by 2 or more hours. Monitor for decreased efficacy of methyldopa if an oral iron preparation is initiated/dose increase, or increased efficacy if discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Iron Preparations may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements as far apart from the administration of an oral iron preparation as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Iron Preparations. Management: Give oral iron products at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Iron Preparations may decrease the serum concentration of Quinolones.  Management: Give oral quinolones at least several hours before (4 h for moxi- and sparfloxacin, 2 h for others) or after (8 h for moxi-, 6 h for cipro/dela-, 4 h for lome-, 3 h for gemi-, and 2 h for enox-, levo-, nor-, oflox-, peflox, or nalidixic acid) oral iron.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir.  Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May decrease the absorption of Iron Preparations. Iron Preparations may decrease the serum concentration of Tetracyclines. Management: Avoid this combination if possible. Administer oral iron preparations at least 2 hours before, or 4 hours after, the dose of the oral tetracycline derivative. Monitor for decreased therapeutic effect of oral tetracycline derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F6789298"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Iron transfer to the fetus is regulated by the placenta (BSH [Pavord 2020]; NAS 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Maternal iron requirements increase during pregnancy. Untreated iron deficiency and iron-deficiency anemia (IDA) in pregnant patients are associated with adverse pregnancy outcomes, including low birth weight, preterm birth, and increased perinatal mortality (ACOG 2021; BSH [Pavord 2020]). Maternal iron deficiency is also associated with fatigue, increased risk of postpartum depression, and possibly postpartum hemorrhage (BSH [Pavord 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Oral and parenteral iron are effective at replacing iron stores in pregnant patients (ACOG 2021). Most studies note iron therapy improves maternal hematologic parameters; however, data related to clinical outcomes in the mother and neonate are limited (FIGO 2019; NAS 2020; USPSTF [Siu 2015]). Use of low-dose supplemental iron is recommended for all pregnant patients beginning in the first trimester or first prenatal visit to prevent anemia at term (ACOG 2021).</p>
<p style="text-indent:0em;margin-top:2em;">A product containing a ferrous salt may be preferred for the oral management of IDA in pregnancy (BSH [Pavord 2020]). Iron supplementation is recommended for 3 months once hemoglobin is within the normal range, and at least 6 weeks postpartum to replenish maternal iron stores (BSH [Pavord 2020]; FIGO 2019). Iron supplementation is recommended in addition to use of prenatal vitamins in pregnant patients diagnosed with IDA (ACOG 2021). Enteric-coated and slow/sustained-release preparations may be less effective due to decreased absorption, and use should be avoided (ACOG 2021; BSH [Pavord 2020]).</p></div>
<div class="block brc drugH1Div" id="F6789301"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Iron is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Endogenous iron concentrations in breast milk vary by postpartum age and are lower than concentrations in the maternal plasma (Dorea 2000; Emmett 1997). Breast milk concentrations of iron are maintained in lactating patients with mild to moderate iron-deficiency anemia (IDA), but concentrations decrease if IDA is moderate to severe (El-Farrash 2012) or severe (Kumar 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">Iron deficiency and IDA are associated with adverse effects in postpartum patients (eg, altered cognition, depression, fatigue) that may influence interactions with the infant. Iron supplementation in the postpartum patient should be initiated as soon as possible following delivery when gestational anemia is a concern. All postpartum patients at risk of gestational anemia (regardless of breastfeeding status) may be given oral iron with or without folic acid for 6 to 12 weeks postpartum to reduce the risk of anemia. A product containing a ferrous salt may be preferred (WHO 2016c). Oral iron therapy is recommended for postpartum patients with uncorrected anemia at delivery who are hemodynamically stable and are asymptomatic or have only mild symptoms; treatment should continue for at least 3 months (BSH [Pavord 2020]).</p></div>
<div class="block dic drugH1Div" id="F6789323"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Dietary sources of iron include beans, cereal (enriched), clams, beef, lentils, liver, oysters, shrimp, and turkey. Foods that enhance dietary absorption of iron include broccoli, grapefruit, orange juice, peppers and strawberries. Foods that decrease dietary absorption of iron include coffee, dairy products, soy products, spinach, and tea.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary reference intake (elemental iron) (IOM 2001):</b></p>
<p style="text-indent:-2em;margin-left:4em;">0 to 6 months: Adequate intake: 0.27 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:4em;">7 to 12 months: Recommended dietary allowance (RDA): 11 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years: RDA: 7 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years: RDA: 10 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 13 years: RDA: 8 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:4em;">14 to 18 years: RDA:</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 11 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 15 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnancy: 27 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Lactation: 10 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:4em;">19 to 50 years: RDA:</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 8 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 18 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Pregnancy: 27 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Lactation: 9 mg <b>elemental </b>iron daily.</p>
<p style="text-indent:-2em;margin-left:4em;">≥50 years: RDA: 8 mg <b>elemental </b>iron daily.</p></div>
<div class="block phk drugH1Div" id="F46174594"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Hematologic response: Red blood cells form within 3 to 10 days; similar onset as parenteral iron salts; Maximum effect: Peak reticulocytosis occurs in 5 to 10 days, and hemoglobin values increase within 2 to 4 weeks </p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Iron is absorbed in the duodenum and upper jejunum; in persons with normal iron stores 10% of an oral dose is absorbed; this is increased to 20% to 30% in persons with inadequate iron stores; food and achlorhydria will decrease absorption</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: To transferrin</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine, sweat, sloughing of intestinal mucosa, and by menses</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F50708339"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Feramax</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ferricure</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Rafofer</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Hong yuan da | Niferex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Niferex | Niferex tlt</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ufer</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Hemacite | Hemodipine | Hemodoctor | Hemonia | Hemostone | Hemotop | Moaferin | Polcaron | Polylon</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Feramax</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Feramax | Ferricure | Polyron</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ferricure</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Calplex | Elezo | Ferrica | Gilcure | Haemfil | Irolex | Ironone | Irosac | Rosefer | Sakride</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fe-tinic | Ferric polysaccharide complex | Ferric x 150 | Hematex iron | Ironup | Novaferrum 50 | Nu-iron</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Dafuten | Ferich | Hemonia | Irome | Niferex</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Niferex</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19881390">
<a name="19881390"></a>Agostoni C, Buonocore G, Carnielli VP, et al. Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2010;50(1):85-91. doi:10.1097/MPG.0b013e3181adaee0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/19881390/pubmed" id="19881390" target="_blank">19881390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  American Academy of Pediatrics Committee on Nutrition. Kleinman RE, Greer FR, eds. <i>Pediatric Nutrition Handbook</i>. 8th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34293770">
<a name="34293770"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No.233: Anemia in pregnancy. <i>Obstet Gynecol</i>. 2021;138(2):e55-e64. doi:10.1097/AOG.0000000000004477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/34293770/pubmed" id="34293770" target="_blank">34293770</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Auerbach M. Treatment of iron deficiency anemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20923825">
<a name="20923825"></a>Baker RD, Greer FR, Committee on Nutrition American Academy of Pediatrics. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). <i>Pediatrics</i>. 2010;126(5):1040-1050.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/20923825/pubmed" id="20923825" target="_blank">20923825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Corkins MR, Balint J, Bobo E, et al, eds. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. 2nd ed. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24135983">
<a name="24135983"></a>Domellöf M, Braegger C, Campoy C, et al. Iron requirements of infants and toddlers. <i>J Pediatr Gastroenterol Nutr</i>. 2014;58(1):119-129. doi:10.1097/MPG.0000000000000206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/24135983/pubmed" id="24135983" target="_blank">24135983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10705077">
<a name="10705077"></a>Dorea JG. Iron and copper in human milk. <i>Nutrition</i>. 2000;16(3):209-220. doi:10.1016/s0899-9007(99)00287-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/10705077/pubmed" id="10705077" target="_blank">10705077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21548016">
<a name="21548016"></a>El-Farrash RA, Ismail EA, Nada AS. Cord blood iron profile and breast milk micronutrients in maternal iron deficiency anemia. <i>Pediatr Blood Cancer</i>. 2012;58(2):233-238. doi: 10.1002/pbc.23184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/21548016/pubmed" id="21548016" target="_blank">21548016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9363415">
<a name="9363415"></a>Emmett PM, Rogers IS. Properties of human milk and their relationship with maternal nutrition. <i>Early Hum Dev</i>. 1997;49(suppl):S7-S28. doi:10.1016/s0378-3782(97)00051-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/9363415/pubmed" id="9363415" target="_blank">9363415</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  EZFE 200 (polysaccharide-iron complex) [prescribing information]. Chattanooga, TN: R.A. McNeil Co; November 2010.</div>
</li>
<li>
<div class="reference">
                  Ferrex 150 (polysaccharide-iron complex) [prescribing information]. Boca Raton, FL: Breckenridge Pharmaceutical Inc; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30710364">
<a name="30710364"></a>FIGO Working Group on Good Clinical Practice in Maternal-Fetal Medicine. Good clinical practice advice: iron deficiency anemia in pregnancy. <i>Int J Gynaecol Obstet</i>. 2019;144(3):322-324. doi:10.1002/ijgo.12740<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/30710364/pubmed" id="30710364" target="_blank">30710364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24479203">
<a name="24479203"></a>
<i>Guideline: Intermittent Iron Supplementation in Preschool and School-Age Children</i>. Geneva: World Health Organization; 2011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/24479203/pubmed" id="24479203" target="_blank">24479203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24215034">
<a name="24215034"></a>Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. <i>Blood.</i> 2014;123(3):326-333. doi:10.1182/blood-2013-10-512624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/24215034/pubmed" id="24215034" target="_blank">24215034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Institute of Medicine (IOM). <i>Nutrition During Lactation</i>. Washington, D.C. The National Academies Press, 1991. Available at <a href="http://www.nap.edu" target="_blank">http://www.nap.edu</a>
</div>
</li>
<li>
<div class="reference">
                  Iron Up (polysaccharide-iron complex) [prescribing information]. Jonesborough, TN: Callion Pharma; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12387433">
<a name="12387433"></a>Kazal LA Jr. Prevention of iron deficiency in infants and toddlers. <i>Am Fam Physician</i>. 2002;66(7):1217-1224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/12387433/pubmed" id="12387433" target="_blank">12387433</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18310187">
<a name="18310187"></a>Kumar A, Rai AK, Basu S, et al. Cord blood and breast milk iron status in maternal anemia. <i>Pediatrics</i>. 2008;121(3):e673-e677. doi: 10.1542/peds.2007-1986.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/18310187/pubmed" id="18310187" target="_blank">18310187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31095091">
<a name="31095091"></a>Lapillonne A, Bronsky J, Campoy C, et al. Feeding the late and moderately preterm infant: a position paper of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2019;69(2):259-270. doi:10.1097/MPG.0000000000002397<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/31095091/pubmed" id="31095091" target="_blank">31095091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22157204">
<a name="22157204"></a>Liu K, Kaffes AJ. Iron deficiency anaemia: a review of diagnosis, investigation and management. <i>Eur J Gastroenterol Hepatol</i>. 2012;24(2):109-116. doi:10.1097/MEG.0b013e32834f3140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/22157204/pubmed" id="22157204" target="_blank">22157204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26289639">
<a name="26289639"></a>Moretti D, Goede JS, Zeder C, et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. <i>Blood</i>. 2015;126(17):1981-1989. doi:10.1182/blood-2015-05-642223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/26289639/pubmed" id="26289639" target="_blank">26289639</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Myferon 150 (polysaccharide-iron complex) [prescribing information]. Richmond, IN: M.E. Pharmaceuticals Inc; February 2014.</div>
</li>
<li>
<div class="reference">
                  National Academies of Sciences, Engineering, and Medicine. <i>Nutrition During Pregnancy and Lactation: Exploring New Evidence: Proceedings of a Workshop</i>. The National Academies Press; 2020. https://doi.org/10.17226/25841.</div>
</li>
<li>
<div class="reference">
                  National Institutes of Health (NIH). Iron fact sheet for health professionals. <a href="https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/" target="_blank">https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/</a>. Published March 30, 2021. Accessed October 28, 2021.</div>
</li>
<li>
<div class="reference">
                  NovaFerrum 125 (polysaccharide-iron complex) [prescribing information]. Corpus Christi, TX: Gensavis Pharmaceuticals Inc; October 2013.</div>
</li>
<li>
<div class="reference">
                  NovaFerrum 50 (polysaccharide-iron complex) [prescribing information]. Corpus Christi, TX: Gensavis Pharmaceuticals Inc; October 2013.</div>
</li>
<li>
<div class="reference">
                  NovaFerrum pediatric drops (polysaccharide-iron complex) [prescribing information]. Corpus Christi, TX: Gensavis Pharmaceuticals, LLC; June 2006.</div>
</li>
<li>
<div class="reference">
                  Nu-Iron (polysaccharide-iron complex) [prescribing information]. Solon, OH: DSE Healthcare Solutions LLC; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8515791">
<a name="8515791"></a>Oski FA. Iron deficiency in infancy and childhood. <i>N Engl J Med</i>. 1993;329(3):190-193. doi:10.1056/NEJM199307153290308<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/8515791/pubmed" id="8515791" target="_blank">8515791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31578718">
<a name="31578718"></a>Pavord S, Daru J, Prasannan N, Robinson S, Stanworth S, Girling J; BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. <i>Br J Haematol</i>. 2020;188(6):819-830. doi:10.1111/bjh.16221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/31578718/pubmed" id="31578718" target="_blank">31578718</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Poly-Iron (polysaccharide-iron complex) [prescribing information]. Madison MS: Cypress Pharmaceutical Inc; March 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28609534">
<a name="28609534"></a>Powers JM, Buchanan GR, Adix L, Zhang S, Gao A, McCavit TL. Effect of low-dose ferrous sulfate vs iron polysaccharide complex on hemoglobin concentration in young children with nutritional iron-deficiency anemia: a randomized clinical trial. <i>JAMA</i>. 2017;317(22):2297-2304. doi:10.1001/jama.2017.6846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/28609534/pubmed" id="28609534" target="_blank">28609534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19161863">
<a name="19161863"></a>Rao R, Georgieff MK. Iron therapy for preterm infants. <i>Clin Perinatol</i>. 2009;36(1):27-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/19161863/pubmed" id="19161863" target="_blank">19161863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9563847">
<a name="9563847"></a>Recommendations to Prevent and Control Iron Deficiency in the United States. Centers for Disease Control and Prevention. <i>MMWR Recomm Rep</i>. 1998;47(RR-3):1-29.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/9563847/pubmed" id="9563847" target="_blank">9563847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3969339">
<a name="3969339"></a>Reeves JD, Yip R. Lack of adverse side effects of oral ferrous sulfate therapy in 1-year-old infants. <i>Pediatrics</i>. 1985;75(2):352-355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/3969339/pubmed" id="3969339" target="_blank">3969339</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Schrier SL, Auerbach M. Treatment of iron deficiency anemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 25, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344176">
<a name="26344176"></a>Siu AL; US Preventive Services Task Force. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: US Preventive Services Task Force Recommendation Statement. <i>Ann Intern Med</i>. 2015;163(7):529-36. doi:10.7326/M15-1707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/26344176/pubmed" id="26344176" target="_blank">26344176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29032957">
<a name="29032957"></a>Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. <i>Lancet Haematol</i>. 2017;4(11):e524-e533. doi:10.1016/S2352-3026(17)30182-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/29032957/pubmed" id="29032957" target="_blank">29032957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31413088">
<a name="31413088"></a>Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. <i>Haematologica</i>. 2020;105(5):1232-1239. doi:10.3324/haematol.2019.220830<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/31413088/pubmed" id="31413088" target="_blank">31413088</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Stoltzfus RJ, Dreyfuss ML, eds; International Nutritional Anemia Consultative Group. Guidelines for the use of iron supplements to prevent and treat iron deficiency anemia. https://www.who.int/nutrition/publications/micronutrients/guidelines_for_Iron_supplementation.pdf?ua=1. Published 1998. Accessed March 20, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31844396">
<a name="31844396"></a>Unger SL, Fenton TR, Jetty R, Critch JN, O'connor DL. Iron requirements in the first 2 years of life. <i>Paediatr Child Health</i>. 2019;24(8):555-556. doi:10.1093/pch/pxz148<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/31844396/pubmed" id="31844396" target="_blank">31844396</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  United Nations Children's Fund, United Nations University, World Health Organization. Iron deficiency anaemia assessment, prevention, and control. A guide for programme managers, 2001.</div>
</li>
<li>
<div class="reference">
                  World Health Organization (WHO). Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers. https://www.ihs.org.in/SHG/WHO-Anemia%20detection%20guidelines.pdf. Published 2001.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27195351">
<a name="27195351"></a>World Health Organization (WHO): Guideline:<i> Daily Iron Supplementation in Adult Women and Adolescent Girls</i>. Geneva<sub>, </sub>Switzerland: World Health Organization; 2016a. <a href="https://www.ncbi.nlm.nih.gov/books/NBK361888/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK361888/</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/27195351/pubmed" id="27195351" target="_blank">27195351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27195348">
<a name="27195348"></a>World Health Organization (WHO): Guideline:<i> Daily Iron Supplementation in Infants and Children</i>. Geneva, Switzerland: World Health Organization; 2016b. <a href="https://www.ncbi.nlm.nih.gov/books/NBK362032/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK362032/</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/27195348/pubmed" id="27195348" target="_blank">27195348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27583315">
<a name="27583315"></a>World Health Organization (WHO): Guideline: <i>Iron supplementation in postpartum women</i>. Geneva: World Health Organization; 2016c.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/27583315/pubmed" id="27583315" target="_blank">27583315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11533326">
<a name="11533326"></a>Zlotkin S, Arthur P, Antwi KY, Yeung G. Randomized, controlled trial of single versus 3-times-daily ferrous sulfate drops for treatment of anemia. <i>Pediatrics</i>. 2001;108(3):613-616. doi:10.1542/peds.108.3.613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polysaccharide-iron-complex-drug-information/abstract-text/11533326/pubmed" id="11533326" target="_blank">11533326</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10222 Version 268.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
